A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Included patients with macular edema due to various etiologies, including diabetes. NA = Not available. Stephen G. Schwartz, Bascom Palmer Eye Institute, University of Miami Miller School of ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up ...

age-related macular degeneration (AMD), macular edema, and diabetic retinopathy. Additionally, an sBLA for Eylea HD is under review by regulators to treat patients with macular edema following retinal ...

Structural biomarkers identifiable on OCT-A can provide details regarding the development and progression of structural changes in MacTel 2.